Pacira Q2 2026 revenue rises 6% to $192.4 million; guidance trimmed for iovera sale
Pacira BioSciences reported second-quarter 2026 total revenue of $192.4 million, up 6% from a year earlier, and GAAP net income of $4.7 million, compared with a net loss a year earlier. Non-GAAP net income and adjusted EBITDA both declined year over year, and the company lowered its full-year 2026 total revenue guidance to reflect the completed sale of its iovera business to Zimmer Biomet.
Key points
- Total revenues were $192.4 million, up from $181.1 million, with EXPAREL net product sales of $147.8 million, up 3%.
- GAAP net income was $4.7 million, or $0.12 per share, versus a net loss of $4.8 million, or $0.11 per share, in Q2 2025; non-GAAP net income was $29.5 million, or $0.75 per share basic, down from $36.0 million.
- Adjusted EBITDA was $48.7 million, compared with $54.3 million in Q2 2025.
- Full-year 2026 total revenue guidance is $735 million to $760 million, down from $745 million to $770 million, reflecting the iovera divestiture that closed July 31, 2026; EXPAREL sales guidance of $600 million to $620 million was reiterate
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 6:57 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 04, 2026.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.